| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BMO Capital analyst Kostas Biliouris maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and maintains $90 price target.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in r...
Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall su...
RBC Capital analyst Leonid Timashev reiterates Legend Biotech (NASDAQ:LEGN) with a Outperform and maintains $86 price target.
Piper Sandler analyst Edward Tenthoff reiterates Legend Biotech (NASDAQ:LEGN) with a Overweight and maintains $90 price target.
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.
Truist Securities analyst Asthika Goonewardene initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Buy rating and anno...
